The revision of revenue guidance to a lower range and the reduction in EPS guidance due to acquisition charges are likely to have a negative short-term impact on Eli Lilly's stock price. The company's investments in tirzepatide supply and balancing demand creation with production are positive long-term strategies but may not offset the immediate negative sentiment from lowered financial expectations.